Table 1.
Patient demographics
| Variable | Controls (n = 102) |
IPF (n = 50) |
BPC (n = 99) |
ACC (n = 41) |
SCC (n = 37) |
LCNEC (n = 7) |
SCLC (n = 16) |
|---|---|---|---|---|---|---|---|
| Mean age, years Range | 50 23–81 |
66 43–87 |
59 22–83 |
65 37–81 |
62 20–85 |
62.7 22–85 |
63.4 31–81 |
| Males:females | 37:65 | 40:10 | 37:62 | 21:20 | 15:22 | 3:4 | 12:4 |
| Tumor histological type/T stage (TNM classification for lung tumors)g | N/A | N/A | TC: 62 (62%)a T1: 46 (75%) T2: 7 (11%) T3: 1 (2%) T4: 4 (6%) No data: 4 (6%) AC: 37 (37%)b T1: 20 (55%) T2: 12 (32%) T3: 3 (8%) T4: 2 (5%) |
T1: 9 (22%) T2: 16 (39%) T3: 2 (5%) T4: 8 (19%) No data: 6 (15%) |
T1: 1 (3%) T2: 10 (27%) T3:6 (16%) T4: 11 (30%) No data: 9 (24%) |
T1: 3 (43%) T2: 3 (43%) T3: 0 (0%) T4: 0 (0%) No data: 1 (14%) |
T1: 0 (0%) T2: 0 (0%) T3: 5 (31%) T4: 10 (63%) No data: 1 (6%) |
| Disease extent (metastatic status) | N/A | N/A | Metastases: 52 (53%) Advanced metastases (distant metastases): 9 (29%) TC: 62 (62%)a N0M0: 21 N+M0: 12 N±M1: 14 AC: 37 (37%)b N0M0: 6 N+M0:11 N±M1: 15 |
Advanced metastatic disease (distant metastases): 20 (49%) |
Advanced metastatic disease (distant metastases): 29 (78%) |
Advanced metastatic disease (distant metastases): 5 (71%) |
Advanced metastatic disease (distant metastases): 15 (94%) |
| Disease status (RECIST 1.1) | N/A | N/A | SDd: 78 (78%) PDe: 21 (21%) |
SD: 10 (24%) PD: 23 (56%) No data: 8 (20%) |
SD: 21 (57%) PD: 15 (30%) No data: 1 (3%) |
SD: 1 (14%) PD: 6 (86%) |
SD:6 (37%) PD: 10 (63%) |
| Current treatment | N/A | N/A | CapTEM: 2 (2%) PRRT: 2 (2%) SSA: 19 (19%)f Currently not treated: 76 (76%) |
Chemotherapya 13 (32%) Before surgery: 16 (39%) Currently not treated: 9 (22%) No data: 3 (7%) |
Chemotherapya 10 (27%) Before surgery: 10 (27%) Currently not treated: 16 (43%) No data: 1 (3%) |
CapTEM: 2 (28%) Currently not treated: 5(72%) |
Chemotherapy: 11 (69%)c Currently not treated: 5 (31%) |
Matched tumor tissue was available from 6 bronchopulmonary carcinoids (BPC) (3 atypical carcinoids [AC]/3 typical carcinoids [TC]), 5 adenocarcinomas (ACC), 5 squamous cell carcinomas (SCC), and 4 small-cell lung cancers (SCLC). All had progressive disease (PD) at the time of surgery. CapTEM, capecitabine and temozolomide; IPF, idiopathic pulmonary fibrosis; LCNEC, large-cell neuroendocrine carcinoma; N/A, not applicable; ND, no data; NED, no evidence of disease; PRRT, peptide receptor radionuclide therapy; SD, stable disease; SSA, somatostatin analog.
This includes 15 with NED. The total number included for staging is 47. Twelve TC exhibited DIPNECH (1 NED, 8 SD, and 3 PD).
This includes 5 with NED. The total number included for staging is 32. One AC exhibited DIPNECH (1 SD).
Cisplatinum-based therapy (with or without vinorelbine or etoposide).
This includes 20 with NED.
Of the patients with PD, 11 were TC and 10 were AC. T1 (no local or distant metastases: n = 4); T2 (local but not distant metastases: n = 4); T2 (local and distant metastases: n = 3); T3 (n = 0); T4 (local metastases only: n = 1); T4 (local and distant metastases: n = 1).
By imaging, 10 were defined as SD on SSAs, and PD was noted in 9.
For ACC and SCC, this is the T classification for lung tumors.